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Diffusion weighted MRIAbstract Background: Methotrexate is widely used chemotherapy especially in pediatric
hematological malignancy. It may associate with acute neurotoxicity. We evaluate the role of the
diffusion-weighted imaging (DWI) in the early detection of the acute methotrexate neurotoxicity.
Methods: Seventeen pediatric patients receiving high-dose methotrexate with clinical manifestation
of neurotoxicity (seizures, headache, aphasia, hemiparesis or altered mental status) were included in
our study. MRI was obtained in all cases within 48 h of onset of symptoms. DWI was done as a part
of the routine MRI study.
Results: In all patients, initial MRI showed abnormal restricted diffusion in the centrum semiovale.
FLAIR is positive in 9 cases showing bright signal. All patients had follow-up MR (within two
weeks); in all cases there was resolution of the diffusion abnormality and interval development
of abnormal signal intensity on FLAIR and T2WI.
Conclusion: Methotrexate can result in reversible neurotoxicity in the form of white matter injury.
DWI may be used in early detection of such changes; therefore, it provides a rapid, noninvasive read-
ily available tool by which neurotoxicity can be early detected and treated. It has the potential to alert
the oncologist to this event and provide a technique by which neurotoxicity can be monitored.
 2015 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Methotrexate (MTX) is an essential chemotherapeutic agent
for the treatment of neoplastic diseases (1). It is an essential
chemotherapeutic drug for acute lymphoblastic leukemia
(ALL) (2). MTX not only prevents central nervous system(CNS) recurrence but also prevents hematologic relapse (3).
MTX crosses the blood–brain barrier; therefore, it can be
administered intravenously or intrathecally for the treatment
of CNS leukemic infiltration (1).
Methotrexate is one of the most common causes of neuro-
toxicity in patients with ALL and it usually affects periventric-
ular deep white matter region (3). Methotrexate toxicity is
often associated with damage to the white matter, termed ‘‘le
ukoencephalopathy” (LEP) (4,5). The reported incidence of
MTX related neurotoxicity for patients with ALL is between
9% and 53% (6).
Table 1 Demographic, clinical and radiological data of our patients.
No Age Sex Diagnosis Neurotoxic
events
Time between IT
MTX and vent
(days)
Time between
event and Initial
MRI (days)
Location of signal
abnormities
DWI FLAIR
1 7 M NHL Altered mental
status
8 0 Bilateral symmetrical
Centrum semiovale
Restricted Negative
2 2 F ALL Seizure 7 1 Bilateral asymmetrical
Centrum semiovale
Restricted Equivocal
3 4 F ALL Seizure 6 2 Bilateral symmetrical
Centrum semiovale
Restricted Negative
4 5 F NHL Left-sided facial
droop, slurred
speech
8 1 Bilateral symmetrical
Centrum semiovale and
splenium
Restricted Equivocal
5 15 M AML Seizure 7 2 Bilateral asymmetrical
Centrum semiovale
Restricted Positive
6 6 F ALL Headache 6 1 Bilateral symmetrical
Centrum semiovale
Restricted Negative
7 5 M AML Altered mental
status
8 2 Bilateral symmetrical
Centrum semiovale.
Restricted Bright
8 17 F ALL Seizure 8 1 Bilateral asymmetrical
Centrum semiovale
Restricted Negative
9 10 F ALL Seizure 10 2 Bilateral symmetrical
Centrum semiovale
Restricted Equivocal
10 5 M AML Headache 6 1 Unilateral Centrum
semiovale
Restricted Negative
11 2 F AML Left-sided facial
droop, slurred
speech
7 1 Bilateral asymmetrical
Centrum semiovale
Restricted Equivocal
12 5 F ALL Seizure 9 0 Bilateral asymmetrical
Centrum semiovale
Restricted Negative
13 3 M AML Headache 8 1 Bilateral symmetrical
Centrum semiovale
Restricted Equivocal
14 7 M ALL Seizure 11 2 Bilateral asymmetrical
Centrum semiovale
Restricted Positive
15 9 F AML Left-sided facial
droop, slurred
speech
7 0 Unilateral Centrum
semiovale
Restricted Negative
16 11 F NHL Seizure 10 0 Bilateral symmetrical
Centrum semiovale
Restricted Negative
17 4 M ALL Seizure 9 0 Bilateral asymmetrical
Centrum semiovale
Restricted Equivocal
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includes various clinical manifestations: convulsion, transient
ischemic attacks, encephalopathy, movement disorders and
myelopathy (1). The risk factors for methotrexate related
toxicity include young age, high-dose, intra-thecal route and
association with cranial radiation (7).
On MRI, the hallmark of MTX related leukoencephalopa-
thy is T2WI hyperintensities, typically located in the periven-
tricular white matter, mainly in the centrum semiovale (7).
Patients often recover from methotrexate-induced neurotoxic-
ity after proper management (8).
Diffusion-weighted imaging (DWI) has become essential in
imaging brain abnormalities and can detect early manifesta-
tion of toxicity secondary to methotrexate in hematological
malignancy pediatric patients (1).
Our aim in this study was to illuminate the role of DWI in
early detection, therefore the prompt management of the acute
MTX neurotoxicity.2. Patients and methods
Diffusion weighted images became a part of the standard proto-
col for all patients at our hospital. After the institutional board
approval, we performed a retrospective review of patients with
hematopoietic malignancy presented with neurological deficits
after intrathecal methotrexate administration during the period
from June 2010 through August 2014. The cases were collected
by searching the division of pediatric oncology database and
PACS system in the diagnostic imaging department.
Seventeen patients with clinical evidence of neurotoxicity
were included. There were 8 cases of acute lymphocytic leuke-
mia (ALL), 6 cases of acute myeloid leukemia (AML) and 3
cases of non-Hodgkin lymphoma (NHL). Symptoms included
headache, seizures, aphasia, hemiparesis or altered mental
status. The medical records were reviewed with attention to
treatment protocol, time of onset of the neurologic events,
recovery from the event, and neuroimaging.
Fig. 1 5 year old female patient with ALL under methotrexate therapy presented with acute right sided facial droop and slurred speech.
MRI done one day after the neurological event. Bilateral symmetrical Centrum semiovale areas of restricted diffusion (a) and reduced
ADC value (b). The splenium of corpus callosum also showed area of restricted diffusion, reduced ADC (d and e), such abnormality these
areas are isointense on FLAIR (c and f).
Child with acute methotrexate related neurotoxicity 1151MR images were obtained with 1.5T scanners (Siemens SP,
Erlangen, Germany). The patients had neurologic events
whose clinical presentation and course were consistent with
possible methotrexate toxicity. The medical records were
reviewed with attention to treatment protocol, time of onset
of the neurologic events, recovery from the event, and
neuroimaging. In addition, there was no other obvious
etiology for the neurologic event (e.g. tumor, hemorrhage or
hypertension).
The imaging sequences consisted of sagittal spin-echo T1,
axial turbo spin-echo (TSE) T2, axial T1WI, axial Fluid
Attenuation Inversion recovery (FLAIR), and DWI with
Apparent Diffusion Coefficient (ADC) map.
We described the radiological and clinical characteristics of
the MTX related neurotoxicity in children with hematological
malignancy.
3. Results
The clinical data of the patients and description of neurotoxic
events are listed in Table 1. There were ten females and seven
males with age range from three to 17 years. There were 8 cases
of ALL, 6 cases of AML and 3 cases of lymphoma.
Symptoms included seizures in ten cases, right-sided facial
droop and slurred speech in three cases, headache in two cases
and altered mental status in two cases.
The MRI was done in the same day of the clinical onset in
five patients, after one day in seven patients and after couple of
days in the other five patients.
The MRI studies were evaluated by two independent
radiologists, and in all patients, the initial MR scan showedabnormal restricted diffusion in the centrum semiovale. We
considered FLIAR images were positive or negative when
the two observed agreed. When they disagreed we conserved
FLAIR findings ‘‘equivocal”. The FLAIR sequence has no
abnormality in nine cases, equivocal in six cases and shows
bright signal only in two cases (Table 1).
In eight of seventeen initial studies, the abnormal diffusion
was symmetrical in both centrum semiovale (Fig. 1); in seven
cases the abnormal signal was more on the left centrum semio-
vale (Fig. 2), and unilateral affection was noted in only two
cases (Fig. 3). The splenium of the corpus callosum was
affected in one case in addition to centrum semiovale affection
(Fig. 1).
All patients had follow-up MR imaging (after two weeks).
There was resolution of the diffusion abnormality with interval
development of abnormal signal intensity on FLAIR and
T2WI noted in all patient (Fig. 2).
4. Discussion
Hematological malignancy is the commonest malignancy in
the pediatric age group. Oral, intravenous, or intrathecal
MTX is widely used for the treatment of pediatric cancer.
The toxicity of MTX is myelosuppression, hepatotoxicity,
nephrotoxicity, mucositis and neurotoxicity with acute or
chronic encephalopathy. Acute encephalopathy usually
develops within 5–14 days after high-dose MTX, which
includes headache, nausea, emesis, lethargy, altered mental
status, blurred vision, aphasia, hemiparesis, and seizure (9).
Till now the exact pathogenesis of methotrexate neurotox-
icity is unclear. There are many theories showed in the
Fig. 2 12 year old female patient withAMLpresented with altered
mental status, after 8 days of high dose methotrexate, initial MRI
showed bilateral asymmetrical areas of restricted diffusion in the
centrum semiovale, more evident in the left side. These areas show
dark signal reduced ADC value. No definite abnormality could be
detected on T1WI (c). The FLAIR signal is equivocal (d).
Fig. 3 5 year old male patient with AML presented 11 days following
shows areas of restricted diffusion with reduced ADC value at the left
detected at the FLAIR (c). Follow-up done 10 days later shows near to
ADC value (d and e). FLAIR images (f) show areas of bright signal i
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have a direct toxic effect on axons, secondary to inhabitation
of the folic acid metabolism. In the study done by Quinn
et al. they found elevated levels of homocysteine and
neurotransmitters in patients exposed to methotrexate so they
presumed that elevated homocysteine and its excitatory amino
acid metabolites mediate, in part, methotrexate-associated
neurotoxicity (10).
The degree of the methotrexate neuro-toxicity is multifacto-
rial, depending upon the specific clinical situation including
dose, route of administration and other neurotoxic medica-
tions (7,11).
Rollin et al. found the neurological manifestation associated
with the methotrexate neurotoxicity is fairly common, with
recent estimates of the incidence of transient motor paralysis
or seizures ranging up to 10% of patients receiving this therapy.
The commonest neurological manifestation associated with
methotrexate toxicity is seizures and altered mental status
and acute stroke like symptoms are also encountered (12).
The typical presentation of the methotrexate associated
leukoencephalopathy on MR imaging, is T2 and FLAIR
hyperintensity signals located in the periventricular white mat-
ter, especially in the centrum semiovale (3). In addition the
splenium of corpus callosum may also be involved (2).
In our study all patients show bilateral symmetrical, asym-
metrical or unilateral centrum semiovale lesions, and in one
patient the splenium of the corpus callosum was involved.
Diffusion-weighted imaging (DWI) is a rapid noninvasive
MRI technique used in imaging of brain abnormalities. In
our patients, the initial MRI scan showed abnormal restricted
diffusion in the centrum semiovale in all cases whereas the
FLAIR was positive only in two cases and equivocal in other
three cases. Such restricted diffusion in the white matter wasintrathecal methotrexate with severe headache, initial MRI study
Centrum semiovale (a and b). No definite abnormalities could be
tal resolution of the restricted diffusion and slight elevation of the
n the left centrum semiovale.
Child with acute methotrexate related neurotoxicity 1153almost reversed in all cases in the follow-up studies when
abnormal FLAIR signal was evident.
DWI is extremely sensitive in the detection of cytotoxic
edema, i.e. hyperacute ischemia. DWI abnormalities are usu-
ally indicative of irreversible cytotoxic injury. Yet very few
cases of reversible DWI abnormalities have been reported
which include patients with sustained seizure activity and
patients with thromboembolic events who underwent rapid
thrombolytic therapy. The restricted diffusion encountered in
the cases of methotrexate neurotoxicity may be consistent with
the proposed mechanisms of a direct neurotoxic effect of
methotrexate on the cell. Yet the reversibility of the MR
abnormalities as well as the resolution of symptoms in our
patients suggests that this acute MTX related cellular swelling
is not necessarily irreversible (3).
Our results are consistent more with the theory attributed
the toxicity to a transient metabolic encephalopathy leading
to cytotoxic edema in cerebral white matter. Such transient
neurological syndrome associated with reversible DWI abnor-
malities due to intramyelinic edema has been described in acute
exacerbations of leukodystrophy and in post-ictal events (13).
5. Conclusion
The high dose methotrexate can result in reversible neurotox-
icity in the form of white matter injury. DWI is accurate in
early detection of such changes; therefore, it provides a rapid,
noninvasive, readily available, accurate tool by which neuro-
toxicity can be early detected and treated. Cytotoxic edema
best explains our patient’s clinical and radiographic findings.
The reorganization of such pattern of chemotherapeutic
induced neurotoxicity is important to avoid unnecessary
workup and invasive procedures in such patients. It has the
potential to alert the oncologist to this event and provide a
technique by which neurotoxicity can be monitored.
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